Sulfate ion

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Sulfate ion

Accession Number

DB14546

Description

Not Available

Type

Small Molecule

Groups

Experimental, Investigational

Structure

Similar Structures

Weight: Average: 96.063
Monoisotopic: 95.951729178
Chemical Formula: O₄S

Synonyms

Sulfate
Sulfate dianion
Sulfate(2-)
Sulfuric acid ion(2-)

Pharmacology

Indication: Not Available
Contraindications & Blackbox Warnings: Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Learn about our commercial Adverse Effects data.
Learn More
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
Acetazolamide	The risk or severity of adverse effects can be increased when Acetazolamide is combined with Sulfate ion.
Aclidinium	The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aclidinium.
Alfentanil	The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Alfentanil.
Alloin	The risk or severity of adverse effects can be increased when Sulfate ion is combined with Alloin.
Almasilate	The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Almasilate.
Aluminium	The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aluminium.
Aluminium phosphate	The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aluminium phosphate.
Aluminum hydroxide	The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Aluminum hydroxide.
Amantadine	The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Amantadine.
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Sulfate ion.

Additional Data Available

Extended Description

Available for Purchase

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

Available for Purchase

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

Available for Purchase

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

Available for Purchase

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

Products

Purchasing individual compounds or compound libraries for your research?

Learn More

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Loa Freedom S	Capsule	100 g/1001	Oral	LOA BIO INC.	2020-11-09	Not applicable

Additional Data Available

Application Number

Available for Purchase

A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

Learn more

Product Code

Available for Purchase

A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

Learn more

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Rurina	Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)	Liquid	Topical	TELOM-X GENE Co., Ltd.	2017-07-01	Not applicable
Rurina	Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)	Liquid	Topical	Nano Bio Tech Co.,Ltd	2017-07-01	Not applicable
Telom-X-gene	Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)	Liquid	Topical	TELOM-X GENE Co., Ltd.	2017-07-01	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Loa Freedom S	Sulfate ion (100 g/1001)	Capsule	Oral	LOA BIO INC.	2020-11-09	Not applicable
Rurina	Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)	Liquid	Topical	TELOM-X GENE Co., Ltd.	2017-07-01	Not applicable
Rurina	Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)	Liquid	Topical	Nano Bio Tech Co.,Ltd	2017-07-01	Not applicable
Telom-X-gene	Sulfate ion (3.6 g/1L) + Chloride ion (0.11 g/1L) + Potassium cation (0.25 g/1L)	Liquid	Topical	TELOM-X GENE Co., Ltd.	2017-07-01	Not applicable

Chemical Identifiers

UNII: 7IS9N8KPMG
CAS number: 14808-79-8
InChI Key: QAOWNCQODCNURD-UHFFFAOYSA-L
InChI: InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)/p-2
IUPAC Name: sulfate
SMILES: [O-]S([O-])(=O)=O

References

General References

Not Available

External Links

Human Metabolome Database: HMDB0001448
ChemSpider: 1085
BindingDB: 26992
RxNav: 1426598
ChEBI: 16189
PDBe Ligand: SO4
Wikipedia: Sulfate

PDB Entries

101m / 102m / 103m / 104m / 105m / 106m / 107m / 108m / 109m / 110m …

show 20965 more

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Diagnostic	Cathartic Colon	1
4	Completed	Treatment	Inflammatory Bowel Diseases (IBD) / Iron Deficiency	1
4	Not Yet Recruiting	Treatment	Anemia of Prematurity / Very Low Birth Weight Infant	1
4	Recruiting	Treatment	Chronic Kidney Disease (CKD) / Kidney Insufficiency, Chronic	1
4	Unknown Status	Diagnostic	Colonoscopy	1
4	Unknown Status	Diagnostic	Preeclampsia	1
4	Unknown Status	Treatment	Deep Neuromuscular Blockade / Magnesium Sulfate / Neuromuscular Blockade / Rocuronium	1
4	Unknown Status	Treatment	Inflammatory Bowel Diseases (IBD) / Iron Deficiency Anemia (IDA)	1
4	Unknown Status	Treatment	Iron Deficiency Anemia (IDA) / Iron-Deficiency Anemias / Pregnancy	1
3	Active Not Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Capsule	Oral	100 g/1001
Liquid	Topical
Solution	Intravenous	12 g/L

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
logP	-0.84	ChemAxon
pKa (Strongest Acidic)	-3	ChemAxon
Physiological Charge	-2	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	80.26 Å²	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	11.53 m³·mol^-1	ChemAxon
Polarizability	5.81 Å³	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available